ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2020

9:00AM-11:00AM: Abstract Number: 1265

2019 Lupus Classification Criteria Score Predicting Cost of Future Hospitalizations

SLE – Diagnosis, Manifestations, & Outcomes Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1120

A Comparison of Opioid-Related Outcomes Among Commercially-Insured Osteoarthritis Patients Treated with Tramadol vs. Non-Tramadol Opioids

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 1091

A Computer-Aided Diagnostic System for Quantitative Scoring of Extent of Interstitial Lung Disease (ILD) in Dermatomyositis/Polymyositis Associated ILD

Muscle Biology, Myositis & Myopathies Poster

9:00AM-11:00AM: Abstract Number: 1370

A Delayed Effect of Tumor Necrosis Factor Inhibitors on Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: Long-term Results from the German Spondyloarthritis Inception Cohort

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

9:00AM-11:00AM: Abstract Number: 1317

A Large Agreement Between the Pain Points of the ACR 1990 Fibromyalgia Criteria and the MASES Enthesitis Score Is Observed in Patients with Axial Spondylitis, Including in Patients Without Concomitant Fibromyalgia

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Extra-MSK & Comorbidities

9:00AM-11:00AM: Abstract Number: 1126

A Mobile Mindfulness Meditation Program May Improve Health-Related Quality of Life for Patients with Rheumatic Disease, a Pilot Study

Patient Outcomes, Preferences, & Attitudes Poster II: Miscellaneous Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1290

A Multitrait-Multimethod Matrix Approach to the Construct Validity of Patient Reported Outcomes Measurement Information System Computerized (PROMIS) Adaptive Tests (CAT) in Systemic Lupus Erythematous

SLE – Diagnosis, Manifestations, & Outcomes Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1074

A Novel Autoantibody Recognizing a 65-kDa Protein Is Associated with Scleromyositis with Head Drop and/or Bent Spine

Muscle Biology, Myositis & Myopathies Poster

9:00AM-11:00AM: Abstract Number: 1388

A Systematic Assessment of Demographics, Clinical and Serological Features Associated with Colonic Hypomotility in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 1412

A T Cell Intrinsic Role for Nod2 in Suppression of Th17-Mediated Experimental Arthritis and Uveitis: Implications for Blau Syndrome

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 1090

Abnormal HDL Antioxidant Function Is Associated with Longitudinal Change in Lung Physiology in Dermatomyositis/Polymyositis Associated Lung Disease

Muscle Biology, Myositis & Myopathies Poster

9:00AM-11:00AM: Abstract Number: 1137

Access to Digital Health in an Urban Rheumatology Population

Patient Outcomes, Preferences, & Attitudes Poster II: Miscellaneous Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1353

Achievement of Remission Is Associated with Improvement in Functionality in Certolizumab Pegol-Treated Patients with Psoriatic Arthritis, Irrespective of Pre-Existing Radiographic Structural Damage

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

9:00AM-11:00AM: Abstract Number: 1083

Alterations of Lipid Profile in IIM Patients Are Associated with Disease Activity, Duration, and Glucocorticoid Treatment

Muscle Biology, Myositis & Myopathies Poster

9:00AM-11:00AM: Abstract Number: 1429

An Evaluation of Real World Use of Biologics in Rare Systemic Vasculitides During Routine Clinical Care in the US

Vasculitis – ANCA-Associated Poster

1
2
3
…
37
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].